On June 14, 2018, the U.S. Food and Drug Administration (FDA) approved the first generic versions of Suboxone (buprenorphine and naloxone) sublingual film (applied under the tongue) for use as medication-assisted treatment for opioid dependence. The branded drug Suboxone is marketed by Indivior, Plc. The generics are made by Mylan Technologies Inc. and Dr. Reddy's Laboratories SA. The FDA approved the generics in multiple strengths. Generic oral tablet buprenorphine-naloxone formulations have been available in the United States since 2013. Indivior was spun out from Reckitt Benckiser in 2014. Suboxone Film generates 80% of Indivior’s annual . . .